Customer Complaints and Inquiries Sample Clauses

Customer Complaints and Inquiries. Eyetech or Gilead, as the case may be, shall give the other party written notice within forty-eight (48) hours of initial receipt of any information it receives regarding the safety of the Product, including any confirmed or unconfirmed information on adverse events possibly associated with the use of the Product; provided that Eyetech's obligation to provide Gilead with such notices shall be limited to information received by Eyetech that Eyetech determines relates to, or is reasonably likely to relate to, the Specifications or Gilead's Manufacturing activities under this Agreement. Eyetech or Gilead, as the case may be, shall notify the other party of any complaint or investigation relating to the Product promptly upon receipt; provided, that, all complaints concerning suspected or actual Product tampering, contamination or mix-up (e.g., wrong ingredients) shall be delivered within twenty-four (24) hours of receipt. Gilead shall provide all assistance reasonably requested by Eyetech in investigating customer complaints regarding the Product (including testing of the Product in accordance with Eyetech's specifications) that, in Eyetech's reasonable opinion, caused by the Manufacturing of such Product. Such testing shall be at Eyetech's expense unless it is finally determined pursuant to Section 5.10 that such Product did not comply with the Product Warranty. Eyetech shall be responsible for responding to all customers' inquiries and/or complaints relating to the Product and the recordkeeping relating thereto. Gilead and Eyetech shall also comply with the requirements set forth in the Quality Agreement relating to the investigation of customer complaints. Eyetech and Gilead shall each provide the other with copies of any annual reports relating to the Product that it is required to submit to the FDA; provided that each party shall be entitled to redact from such copies confidential information that is not reasonably related to the other party's ongoing performance of its activities with respect to the Product.
Sample 1Sample 2
AutoNDA by SimpleDocs
Customer Complaints and Inquiries. The Parties intend that customer complaints and inquiries shall be initially received by Roche, which shall log the complaint or inquiry [ * ] whether a response [ * ] is most appropriate, depending upon whether the complaint or inquiry relates to [ * ], all in accordance with [ * ] to [ * ] by [ * ] set forth in the Commercialization Plan. Aspreva shall be responsible for responding to complaints and inquiries relating primarily to the Aspreva Commercialization Activities and Roche shall be responsible for responding to all other complaints and inquiries; provided, however, that Roche shall in any event inform Aspreva of any complaint or inquiry (or issues related thereto) that would materially effect Aspreva's rights or obligations under this Agreement.
Sample 1Sample 2
Customer Complaints and Inquiries. LFB Biotech shall be responsible for receiving and addressing all customer complaints and inquiries regarding Products in the European Territory. GTC shall be responsible for receiving and addressing all customer complaints and inquiries regarding Products in the North American Territory. The JSC shall determine, on a country-by-country or region-by-region basis, which Operating Party shall be responsible for receiving and addressing customer complaints and inquiries regarding Products in the Co-Exclusive Territory. Following receipt of any customer complaint or inquiry, the responsible Operating Party shall log the complaint or inquiry and determine the appropriate response, in accordance with applicable laws and regulations and the procedures established by the JSC and set forth in the applicable Commercialization Plan; provided, that the Operating Party responsible for addressing any complaint or inquiry shall promptly notify the other Parties after receiving any material complaint or inquiry and shall consult with the other Operating Party prior to taking any action in response thereto that would materially affect the other Party’s rights or obligations under this Agreement.
Sample 1
Customer Complaints and Inquiries a) Safety Related Complaints: COMPANY shall give PFIZER written notice within four (4) Business Days of initial receipt of any information it receives regarding the safety of the Product(s), including any confirmed or unconfirmed information on adverse events possibly associated with the use of the Product(s). COMPANY shall notify PFIZER of any complaint or investigation relating to the Product(s) promptly upon receipt by COMPANY; provided, that, all complaints concerning suspected or actual Product(s) tampering, contamination or mix-up (e.g., wrong ingredients) shall be delivered to PFIZER within one (1) Business Day of receipt. COMPANY shall provide all assistance requested by PFIZER in investigating customer complaints regarding the Product(s) (including testing of the Product(s) in accordance with PFIZER’s specifications at COMPANY’s expense) that, in PFIZER’s reasonable opinion, are related to or arise from the manufacturing of such Product(s). PFIZER shall be responsible for responding to all customers’ complaints relating to the Product(s) and the record keeping relating thereto. COMPANY and PFIZER shall also comply with the requirements set forth in the Quality Agreement relating to the investigation of customer complaints.
Sample 1
Customer Complaints and Inquiries. Company shall provide all assistance reasonably requested by Rxxx’x in investigating customer and consumer complaints regarding any Product. Company shall be responsible for responding to all material customers’ and consumers’ inquiries and/or complaints relating to the Products and the recordkeeping relating thereto.
Sample 1
Customer Complaints and Inquiries. A. Under Normal Operating Conditions, the Franchisee shall investigate Subscriber complaints referred by the LFA within five (5) business days. The Franchisee shall notify the LFA of those matters that necessitate an excess of five (5) business days to resolve, but those matters must be resolved within fifteen (15) days of the initial complaint. The LFA may require reasonable documentation to be provided by the Franchisee to substantiate the request for additional time to resolve the problem. For purposes of this Section, "resolve" means that the Franchisee shall perform those actions, which, in the normal course of business, are necessary to investigate the Customer's complaint and advise the Customer of the results of that investigation.
Sample 1

Related to Customer Complaints and Inquiries

  • Customer Complaints Each party hereby agrees to promptly provide to the other party copies of any written or otherwise documented complaints from customers of Dealer received by such party relating in any way to the Offering (including, but not limited to, the manner in which the Shares are offered by the Dealer Manager or Dealer), the Shares or the Company.

  • Complaints and Investigations 1. This article applies to complaints or allegations made externally and not from normal supervisory activities.

  • Inquiries Respond to telephonic, mail, and in-person inquiries from Institutions, Account holders, or their representatives requesting information regarding matters such as shareholder account or transaction status, net asset value ("NAV") of Series shares, Series performance, Series services, plans and options, Series investment policies, Series portfolio holdings, and Series distributions and taxation thereof;

  • Product Complaints Subdistributor shall promptly notify Distributor of (but in no event later than 24 hours after receipt), and provide, upon Distributor’s request, reasonable assistance to address and investigate, any complaint or adverse claim about any Product or its use of which Subdistributor becomes aware;

  • Complaints If you have a complaint relating to the sale of energy by us to you, or this contract generally, you may lodge a complaint with us in accordance with our standard complaints and dispute resolution procedures. Note: Our standard complaints and dispute resolution procedures are published on our website.

  • Due Diligence Review; Information The Company shall make available, during normal business hours, for inspection and review by the Investors, advisors to and representatives of the Investors (who may or may not be affiliated with the Investors and who are reasonably acceptable to the Company), all financial and other records, all SEC Filings (as defined in the Purchase Agreement) and other filings with the SEC, and all other corporate documents and properties of the Company as may be reasonably necessary for the purpose of such review, and cause the Company’s officers, directors and employees, within a reasonable time period, to supply all such information reasonably requested by the Investors or any such representative, advisor or underwriter in connection with such Registration Statement (including, without limitation, in response to all questions and other inquiries reasonably made or submitted by any of them), prior to and from time to time after the filing and effectiveness of the Registration Statement for the sole purpose of enabling the Investors and such representatives, advisors and underwriters and their respective accountants and attorneys to conduct initial and ongoing due diligence with respect to the Company and the accuracy of such Registration Statement. The Company shall not disclose material nonpublic information to the Investors, or to advisors to or representatives of the Investors, unless prior to disclosure of such information the Company identifies such information as being material nonpublic information and provides the Investors, such advisors and representatives with the opportunity to accept or refuse to accept such material nonpublic information for review and any Investor wishing to obtain such information enters into an appropriate confidentiality agreement with the Company with respect thereto.

  • Medical Inquiries Promptly after the Registrations have been transferred to Buyer, Buyer shall assume all responsibility for all correspondence and communication with physicians and other health care professionals and customers in the applicable Territory relating to the CV Products. After the Closing Date, Buyer and Seller shall work together towards an orderly transition of the responsibility for all correspondence and communication with health care professionals and customers in the applicable Territory relating to the CV Products. Seller shall continue to be responsible for such correspondence and communication under the direction of Buyer until the Registrations have been transferred to Buyer. Buyer shall keep such records and make such reports as shall be reasonably necessary to document such communications in compliance with all applicable regulatory requirements. After transfer of responsibility to Buyer pursuant to this Article 10, Seller shall, except in the case of medical emergency, refer all questions relating to the CV Products raised by health care professionals and customers to Buyer for its response.

  • Adverse Events Subsequent to the date hereof, there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York Stock Exchange, the NASDAQ National Market or the NASDAQ Global Market, (ii) a general moratorium on commercial banking activities in the People’s Republic of China or New York, (iii) the outbreak or escalation of hostilities involving the United States or the People’s Republic of China or the declaration by the United States or the People’s Republic of China of a national emergency or war if the effect of any such event specified in this clause (iii) in your reasonable judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus, or (iv) such a material adverse change in general economic, political, financial or international conditions affecting financial markets in the United States or the People’s Republic of China having a material adverse impact on trading prices of securities in general, as, in your reasonable judgment, makes it impracticable or inadvisable to proceed with the public offering of the Shares or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus.

Time is Money Join Law Insider Premium to draft better contracts faster.